Stańczak J., Podstawowe informacje o rozwoju demograficznym Polski do 2014 roku, www.stat.gov.pl.
Mills A. D., Nazer M. Z., Haddadin M. J., Kurth M. J., N,N-Bond-Forming Heterocyclization: Synthesis of 3-Alkoxy-2H-indazoles, J. Org. Chem, 2006, 71, 2687-2689.
DOI: https://doi.org/10.1021/jo0524831
Elliott E. L., Bushell S. M., Cavero M., Tolan B., Kelly T. R., Total Synthesis of Nigellicine and Nigeglanine Hydrobromide, Org. Lett. 2005, 7 (12), 2449-2451.
Gaikwad D. D., Chapolikar A. D., Devkate C. G., Warad K. D., Tayade A. P., Pawar R. P., Domb A. J., Synthesis of indazole motifs and their medicinal importance: An overview, Eur. J. Med. Chem., 2015, 90, 701-731.
DOI: https://doi.org/10.1016/j.ejmech.2014.11.029
Fischer E., Seuffert O., Ueber das Indazol, Eur. J. Inorg. Chem., 1901, 34 (1), 795-798.
DOI: https://doi.org/10.1002/cber.190103401137
Minkin Y. I., Garnovskii A. D., Elguero J., Katritzky A. R., Denisko O. V., The Tautomerism of Heterocycles, Five-Membered Rings with Two ot More Heteroatoms, Adv. Heterocycl. Chem., 2000, 76, 157-323.
DOI: https://doi.org/10.1016/S0065-2725(00)76005-3
Schmidt A., Beutler A., Snovydovych B., Recent Advances in the Chemistry of indazoles, Eur. J. Org. Chem., 2008, 4073-4095.
DOI: https://doi.org/10.1002/ejoc.200800227
Rahman A., Malik S., Cun-heng H., Clardy J., Isolation and structure determination of nigellicyne, a novel alkaloid from the seeds of nigella sativa, Tetrahedron Lett., 1985, 26, 2759-2762.
DOI: https://doi.org/10.1016/S0040-4039(00)94904-9
Liu Y.-M., Yang J.-S., Liu Q.-H., New Alkaloid and Its Artificial Derivative with an Indazole Ring from Nigella glandulifera, Chem. Pharm. Bull., 2004, 52, 454-455.
DOI: https://doi.org/10.1248/cpb.52.454
Rahman A., Malik S., Hasan S. S., Choudhary M. I., Ni C.-Z., Clardy J., Nigellidine - a new indazole alkaloid from the seeds of nigella sativa, Tetrahedron Lett., 1995, 36, 1993-1996.
DOI: https://doi.org/10.1016/0040-4039(95)00210-4
Abu-Irmaileh B. E., Afifi F. U., Herbal medicine in Jordan with special emphasis on commonly used herbs, J. Etnopharmacol., 2003, 89, 193-197.
DOI: https://doi.org/10.1016/S0378-8741(03)00283-6
Said O., Khali K., Folder S., Azaizeh H., Ethnopharmacological survey of medicinal herbs in Israel, the Golan Heights and the West Bank region, J. Ethnopharmacol., 2002, 83, 251-265.
DOI: https://doi.org/10.1016/S0378-8741(02)00253-2
Eddouks N., Maghrani M., Lemhadri A., Quahidi M. L., Jouad H., Ethnopharmacological survey of medicinal plants used for the treatment of diabetes mellitus, hypertension and cardiac diseases in the south-east region of Morocco (Tafilalet), J. Ethnopharmacol., 82, 2002, 97-103.
DOI: https://doi.org/10.1016/S0378-8741(02)00164-2
Elliott E. L., Bushell S. M., Cavero M., Tolan B., Kelly T. R., Total Synthesis of Nigellicine and Nigeglanine Hydrobromide, Org. Lett. 2005, 7 (12), 2449-2451.
DOI: https://doi.org/10.1021/ol050769m
Inamoto K., Katsuno M., Yoshino T., Arai Y., Hiroya K., Sakamoto T., Synthesis of 3-substituted indazoles and benzoisoxazoles via Pd-catalyzed cyclization reactions, applications to the synthesis of nigellicyne, Tetrahedron 2007, 63, 2695-2711.
DOI: https://doi.org/10.1016/j.tet.2007.01.010
Thangadurai A., Minu M., Wakode S., Agrawal S., Narasimhan B., Indazole: a medicinally important heterocyclic moiety, Med. Chem. Res. 2012, 21, 1509-1523.
DOI: https://doi.org/10.1007/s00044-011-9631-3
Albert D. H., Tapang P., Magoc T. J., Pease L. J., Reuter D. R., Wei R. Q., Li J., Guo J., Bousquet P. F., Ghoreishi-Haack N. S., Wang B., Bukofzer G. T., Wang Y. C., Stavropoulos J. A., Hartandi K., Niquette A. L., Soni N., Johnson E. F., McCall J. O., Bouska J. J., Luo Y., Donawho C. K., Dai Y., Marcotte P. A., Glaser K. B., Michaelides M. R., Davidsen S. K., Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor, Mol. Cancer Ther. 2006, 5, 995-1006.
DOI: https://doi.org/10.1158/1535-7163.MCT-05-0410
Luo Y., Jiang F., Cole T. B., Hradil V. P., Reuter D., Chakravartty A., Albert D. F., Davidsen S. K., Cox B. F., McKeegan E. M., Fox G. B., A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model, Cancer Chemother. Pharmacol. 2012, 69, 911-921.
DOI: https://doi.org/10.1007/s00280-011-1740-7
Wilhelm S. M, Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L, Lynch M., Auclair D., Taylor I. Gedrich R. Voznesensky A., Riedl B., Post L. E., Bollag G., Trail P. A., BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases ivolved in tumor progression and angiogenesis, Cancer Res. 2004, 64, 7099-7109.
DOI: https://doi.org/10.1158/0008-5472.CAN-04-1443
Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R. A., Schwartz B., Simantov R., Kelley S., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, Nat. Rev. Drug Discov. 2006; 5, 835-844.
DOI: https://doi.org/10.1038/nrd2130
Chu J.-H., Zhao C.-R., Song Z.-Y., Wang R.-Q., Qin Y.-Z., Wen-Bao Li W.-B., , Xian-Jun Quo X.-J., 1082-39, an analogue of sorafenib, inhibited human cancer cell growth more potently than sorafenib, Biomed. Pharmacother. 2014, 68, 335-341.
DOI: https://doi.org/10.1016/j.biopha.2014.01.010
Zhao C., Wang R., Li G. Xue X., Sun C., Qu X., Li W., Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines, Bioorg. Med. Chem. Lett. 2013, 23, 1989-1992.
DOI: https://doi.org/10.1016/j.bmcl.2013.02.034
Lu Y.-Y., Wang J.-J., Zhang X.-K., Li W.-B., Guo X.-L., 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases, Journal of Pharmacy and Pharmacology, 2015, 67, 1393-1405.
DOI: https://doi.org/10.1111/jphp.12440
Shan Y., Dong J., Pan X., Zhang L. Zhang J., Dong Y., Wang M., Expanding the structural diversity of Bcr-Abl inhibitors, dibenzoylpiperazin incorporated with 1H-indazol-3-amine, Eur. J. Med. Chem. 2015, 104, 139-147.
DOI: https://doi.org/10.1016/j.ejmech.2015.09.034
Lee J., Kim J., Hong V. S., Park J.-W., Synthesis and anti-proliferative activity evaluation of N3-acyl-N5-aryl-3,5-diaminoindazole analogues as anti-head and neck cancer agents, DARU J. Pharm. Sci. 2014, 22, 4-12.
DOI: https://doi.org/10.1186/2008-2231-22-4
Song P., Chen M., Ma X., Xu L., Tao T., Yubo Zhou Y., Hu Y., Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold, Bioorg. Med. Chem. 2015, 23, 1858-1868.
DOI: https://doi.org/10.1016/j.bmc.2015.02.004
Abbassi N., Geffken D., Aiello C., Gangemi R. Rosano C., Viale M., Synthesis, antiproliferative and apoptotic activities of N-(6(4)-indazolyl)-benzenesulfonamide derivatives as potential anticancer agents, Eur. J. Med. Chem. 2012, 57, 240-249.
DOI: https://doi.org/10.1016/j.ejmech.2012.09.013
Abbassi N., Rakib El M., Chicha H., Bouissane L., Hannioui A., Aiello C., Gangemi R., Castagnola P., Rosano C., Viale M., Synthesis and antitumor activity of some substituted indazole derivatives, Arch. Pharm. Chem. Life Sci., 2014, 347, 423-431.
DOI: https://doi.org/10.1002/ardp.201300390
Borst D. L., Arruda L. S., MacLean E., Pithavala Y. K., James E. Morgado J. E., Common questions regarding clinical use of axitinib in advanced renal cell carcinoma, Am. J. Health-Syst. Pharm. 2014, 71, 1092-1096.
DOI: https://doi.org/10.2146/ajhp130581
Chen Y., Tortorici M. A., Garrett M., Hee B., Klamerus K. J., Pithavala Y. K., Clinical pharmacology of Axitinib, Clin. Pharmacokinet. 2013, 52, 713-725.
DOI: https://doi.org/10.1007/s40262-013-0068-3
Pemovska T., Johnson E., Kontro M., Rapasky G. A., Chen J., Wells P., Cronin C. N., McTigue M., Kallioniemi O., Porkka K., Murray B. W., Wennerberg K., Axitinib effectively inhibits BCR-ABL1 (T316l) with a distinct binding conformation, Nature 2015, 519, 102-115.
DOI: https://doi.org/10.1038/nature14119
Floridi A., Paggi M. G., Marcante M. L., Silvestrini B., Caputo A., De Martino C. J. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cell, Natl. Cancer. Inst. 1981, 66, 497-499.
Pelicano H., Martin D. S., Xu R.-H., Huang P., Glycolysis inhibition for anticancer treatment, Oncogene 2006, 25, 4633-4646.
DOI: https://doi.org/10.1038/sj.onc.1209597
Di Cosimo S., Ferretti G., Papaldo P., Carlini P., Fabi A., Cognetti F., Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors, Drugs Today Barc. 2003, 39, 157-174.
DOI: https://doi.org/10.1358/dot.2003.39.3.799451
De Lena M., Lorusso V., Latorre A., Fanizza G., Gargano G., Caporusso L., Guida M., Catino A., Crucitta E., Sambiasi D., Mazzei A., Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study, Eur. J. Cancer 2001, 37, 364-368.
DOI: https://doi.org/10.1016/S0959-8049(00)00400-7
Laufer R., Forrest B., Li S.-W., Liu Y., Sampson P., Edwards L., Lang Y., Awrey D. E., Mao G., Plotnikova O., Leung G., Hodgson R., Beletskaya I., Mason J. M., Luo X., Xin Wei, Yao Y., Feher M., Ban F., Reza Kiarash R., Green E., Mak T. W., Pan G., Pauls H. W, The discovery of PLK4 inhibitors: (E) 3-((1H-indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents, J. Med. Chem. 2013, 56, 6069-6087.
DOI: https://doi.org/10.1021/jm400380m
Sampson P. B., Liu Y., Patel N. K., Feher M., Forrest B., Li S.-W., Edwards L., Laufer R., Lang Y., Ban F., Awrey D. E., Mao G., Plotnikova O., Leung G., Hodgson R., Mason J., Wei X., Kiarash R., Green E., Qiu W., Chirgadze N. Y., Mak T. W., Pan G., Pauls H. W., The discovery of polo-like kinase 4 inhibitors, design and optimization of spiro[cyclopropane-1,3’[3H]indol]-2’(1’H)-ones as orally bioavailable antitumor agents, J. Med. Chem. 2015, 58, 130-146.
DOI: https://doi.org/10.1021/jm500537u
Sampson P. B, Liu Y., Forrest B., Cumming G., Li S.-W., Patel N. K., Edwards L., Laufer R., Feher M., Ban F., Awrey D. E., Mao G., Plotnikova O., Hodgson R, Beletskaya I., Mason J. M., Luo X., Nadeem V., Wei X., Kiarash R., Madeira B., Huang P., Mak T. W., Pan G., Pauls H. W., The discovery of polo-like kinase 4 inhibitors: identification of (1R,2S)-2-(3-((E)-4-(((cis)-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5’-methoxyspiro[cyclopropane-1,3’-indolin]-2’-one (CFI-400945) as a potent orally active antitumor agent, J. Med. Chem. 2015, 58, 147-169.
DOI: https://doi.org/10.1021/jm5005336
Li S.-W., Liu Y., Sampson P. B. Patel N. K., Forrest B. T., Edwards L., Laufer R., Feher M., Ban F., Awrey D. E., Hodgson R., Beletskaya I., Mao G., Mason J. M., Wei X., Luo X., Kiarash R., Green E., Mak T. W., Pan G., Pauls H. W., Design and optimization of (3-aryl-1H-indazol-6-yl)spiro [cyclopropane-1,30 -indolin]-2’ -ones as potent PLK4 inhibitors with oral antitumor efficacy, Bioorg. Med. Chem. Lett. 2016, 26, 4625-4630.
DOI: https://doi.org/10.1016/j.bmcl.2016.08.063
Ye L., Ou X., Tian Y., Yu B., Luo Y., Feng B., Lin H., Zhang J., Wu S., Eur. Indazoles as potential c-met inhibitors: design, synthesis and molecular docking studies, J. Med. Chem. 2013, 65 112-118.
DOI: https://doi.org/10.1016/j.ejmech.2013.04.004
Lai A., Mehmet M., Govek S., Nagasawa J., Bonnefous C., Julien J., Douglas K., Sensintaffar J., Lu N., Lee K., Aparicio A., Kaufman J., Qian J., Shao G., Prudente R., Moon M. J., Joseph J. D., Darimont B., Brigham D., Grillot K., Heyman R., Rix P. J., Hager J. H., Smith N. D., Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts, J. Med. Chem. 2015, 58, 4888-4904.
DOI: https://doi.org/10.1021/acs.jmedchem.5b00054
Govek S.P, Nagasawa J. Y., Douglas K. L., Lai A. G., Kahraman M., Bonnefous C., Aparicio A. M., Darimont B. D., Grillot K. L., Joseph J. D., Kaufman J. A., Lee K.-J., Lu N., Moon M. J., Prudente R. Y., Sensintaffar J., Rix P. J., Hager J. H., Smith N. D., Optimization of an indazole series of selective estrogen receptor degraders: tumor regression in a tamoxifen-resistant breast cancer xerograft, Bioorg. Med. Chem. Lett. 2015, 25, 5163-5167
DOI: https://doi.org/10.1016/j.bmcl.2015.09.074
English
Język Polski
